Company intelligence / Profile preview

Prometheus Biosciences

San Diego, California, United States

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Lead asset PRA023 (now under Merck) showed positive results in Phase 2 trials for ulcerative colitis and Crohn's disease, with data highlighting improvements in both safety and efficacy; additional candidates were in earlier stages at time of acquisition

Therapeutic areas: RheumatologyImmunologyGastroenterology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Partnerships

Cedars Sinai Medical Center (research origin)Merck (acquirer, subsequent pipeline development)

Beyond the preview

Go deeper on Prometheus Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prometheus Biosciences.

Explore the full profile